MELA Sciences, Inc. a Leader in the Fight Against Melanoma, Exhibiting MelaFind(R) at the German Skin Cancer Congress

MELA Sciences, Inc. a Leader in the Fight Against Melanoma, Exhibiting
MelaFind(R) at the German Skin Cancer Congress

IRVINGTON, N.Y., Sept. 25, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc.
(Nasdaq:MELA), the medical device company that has developed and is
commercializing MelaFind®, the first and only FDA approved optical diagnostic
device for melanoma detection used by dermatologists in their fight against
melanoma, will be exhibiting MelaFind® at the German Skin Cancer Congress
(ADO) that will take place in Essen, Germany on September 26-28, 2013. The
DeCOG (Dermatologic Cooperative Oncology Group) is affiliated with the German
Cancer Society (DKG) and the German Dermatologic Society (DDG).

The Congress will be lead by Prof. Dr. Dirk Schadendorf, ADO Congress Chairman
and President, and Director of the Dermatology Department and Clinic at the
University of Essen, and will focus on skin cancer prevention. According to
the organizers, "the majority of patients are not aware that skin cancer is
highly treatable at an early stage, but promising, groundbreaking advances in
research and technology have been made and will be presented at the Congress."

MELA Sciences, Inc. will be exhibiting MelaFind®; a first of its kind, FDA and
CE Mark approved, innovative spectral imaging and lesion data analysis system
that aids and supports dermatologists' biopsy decisions by non-invasively
providing important objective information as deep as 2.5 mm below the skin's

Prof. Dr. Schadendorf and his team at the University of Essen's Dermatology
Clinic have been working with the MelaFind® system for over twelve months.
"MelaFind® provides important images and objective data that helps
dermatologists better understand the structural disorganization of ambiguous
pigmented skin lesions, making it a powerful assist to traditional methods
(ABCDEPRU)," commented Dr. Schadendorf. He further noted that, "New
technologies such as MelaFind® are enriching and complimenting dermatologists'
skin cancer examinations by providing useful data about clinically ambiguous
pigmented skin lesions that are difficult to differentiate from early-stage
melanoma, when the disease is most curable and early detection is most
critical to survival."

MelaFind® has been recognized by the Cleveland Clinic as a Top 10 Medical
Innovation for 2013. Consumers can learn more about the device or locate a
dermatologist with MelaFind® in their area by visiting

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of
its flagship product, MelaFind® and its further design and development.
MelaFind® is a non-invasive tool to provide additional information to
dermatologists during melanoma skin examinations. The device uses light from
visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm
beneath the skin. The device provides information on a lesion's level of
morphologic disorganization to provide additional objective information that
may be used by dermatologists in the biopsy decision-making process. MelaFind®
has been approved by the US Food and Drug Administration for use in the US. In
addition, MelaFind® has received CE Mark approval and is approved for use in
the European Union.

For more information on MELA Sciences, visit

About Association of Dermatologic Oncology (ADO) / Arbeitsgemeinschaft
Dermatologishe Onkologie (ADO)

The DeCOG (Dermatologic Cooperative Oncology Group) is affiliated with the
German Cancer Society (DKG) and the German Dermatologic Society (DDG). Founded
in 1990, it promotes dermato-oncology to increase the quality of care for
patients and to establish standards for skin cancer detection and treatment.
This year's Congress will take place in Essen, Germany from September 26–28,
2013, and will be lead by Prof. Dr. Dirk Schadendorf, Director of the
dermatology clinic at the University of Essen.

Safe Harbor:

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at and

CONTACT: For further information contact:
         Lynn Pieper
         Westwicke Partners
         Erica Sperling
         Rpr Marketing Communications
Press spacebar to pause and continue. Press esc to stop.